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Abstract
Background: Several concepts of treatment in neonatal ARDS have been proposed in the last
years. The present study compared the effects of open lung concept positive pressure ventilation
(PPVOLC) with a conventional ventilation strategy combined with administration of two different
surfactant preparations on lung function and surfactant homoeostasis.
Methods: After repeated whole-lung saline lavage, 16 newborn piglets were assigned to either
PPVOLC (n = 5) or surfactant treatment under conventional PPV using a natural bovine (n = 5) or a
monomeric protein B based surfactant (n = 6).
Results: Comprehensive monitoring showed each treatment strategy to improve gas exchange
and lung function, although the effect on PaO2 and pulmonary compliance declined over the study
period in the surfactant groups. The overall improvement of the ventilation efficiency index (VEI)
was significantly greater in the PPVOLC  group. Phospholipid and protein analyses of the
bronchoalveolar lavage fluid showed significant alterations to surfactant homoeostasis in the
PPVOLC group, whereas IL-10 and SP-C mRNA expression was tendentially increased in the
surfactant groups.
Conclusion: The different treatment strategies applied could be shown to improve gas exchange
and lung function in neonatal ARDS. To which extent differences in maintenance of lung function
and surfactant homeostasis may lead to long-term consequences needs to be studied further.
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Background
In neonatal acute respiratory distress syndrome (ARDS)-
like lung disorders different therapeutic approaches have
been introduced in the last years. These include mechani-
cal ventilation strategies as well as exogenous surfactant
administration. Various animal studies have focussed this
topic and different regimes have been introduced into
clinical practice although large clinical trials have not
been performed yet [1-3]. As shown in experimental stud-
ies, the open lung concept (OLC) as an alternative venti-
lation strategy, improves gas exchange and reduces
ventilator-induced lung injury in models of secondary
surfactant deficiency [4,5]. These effects were seen while
applying the OLC during high-frequency oscillatory venti-
lation an positive pressure ventilation [4]. Furthermore,
histology and biochemical analyses of bronchoalveolar
lavage specimen showed reduced signs of lung injury and
pulmonary inflammation in OLC ventilated animals [5].
However, respiratory failure in term neonates is often
accompanied by secondary surfactant deficiency, contrib-
uting to impairment of lung function in these infants.
Thus, exogenous surfactant administration in neonatal
ARDS-like lung injury is a clinically well established treat-
ment option [1,6,7]. Even in meconium aspiration syn-
drome, leading to severe inflammatory-induced lung
failure, exogenous surfactant administration is part of
therapeutic concepts [8]. Experimentally, the restoration
of pulmonary function and gas exchange as well as the
amelioration of pulmonary inflammatory processes has
been shown [9]. Nevertheless, it has not been extensively
investigated whether surfactant therapy in neonatal ARDS
attains different effects on gas exchange, lung function,
surfactant homoeostasis or pulmonary inflammatory
processes compared to the OLC without surfactant
replacement, although these effects may lead to differ-
ences in short and long term pulmonary outcome follow-
ing neonatal ARDS. Furthermore, there is still no
consensus on ventilation strategy in these infants in com-
bination or without surfactant administration until now
[10].
Concerning the choice of the surfactant preparation
applied, surfactant preparations with altered protein and
phospholipid contents compared to natural surfactant
products have gained increasing interest in treatment of
ARDS-like lung disorders [9,11-16,20] due to their poten-
tial resistance towards surfactant inactivation [17]. Thus,
two different surfactant preparations have been chosen
for surfactant replacement therapy in the present study: A
natural bovine surfactant, frequently used in clinical treat-
ment regimes for neonatal ARDS [18,19] and a modified
monomeric SP-B based bovine surfactant, that had
recently been demonstrated to improve biological activity
of the surfactant preparation compared to standard prep-
arations in a neonatal lung lavage model [20].
Aim of the present study was to compare a treatment strat-
egy applying the OLC without surfactant replacement
with a treatment regime using exogenous surfactant
administration under conventional ventilation for their
effects on gas exchange and lung function variables in a
piglet model of neonatal ARDS. Furthermore, different
variables of the surfactant system have been assessed
using molecular and biochemical analyses of surfactant
proteins (SP) and phospholipid composition in order to
obtain sensitive markers for lung injury processes. Regard-
ing the impact of different treatment strategies on pulmo-
nary inflammatory processes secondary to lavage-induced
lung failure, histologic changes and pulmonary inter-
leukin mRNA expression have been analyzed.
Methods
Animal preparation
The experiments were performed according to the Guide-
lines for the Care and Use of Laboratory Animals of the
National Institutes of Health and were approved by local
authorities of the animal investigation committee.
Anesthesia was performed in 16 newborn piglets, aged 6
± 5 days and at a weight of 3.0 ± 0.5 kg (mean ± SD each)
with ketamine and midazolam after an intramuscular
bolus of ketamine as published previously [9]. The piglets
were tracheotomized, a cuffed endotracheal tube (3.0 mm
inner diameter; Rüsch, Kernen-Rommelshausen, Ger-
many) was introduced into the trachea and connected to
the Evita XL (Dräger, Lübeck, Germany). Animals were
ventilated using a pressure-controlled mode with a peak
inspiratory pressure (PIP) of 9–12 cm H2O, a positive
end-expiratory pressure (PEEP) of 2 cm H2O, and a respi-
ratory rate of 25–30 cycles/min, a rate of inspiration to
expiration of 1:2 at 100% oxygen (FiO2 1.0). Under these
conditions, normocapnia was observed. A neuromuscular
block was induced with pancuromium bromide (0.5 mg/
kg i.v.), followed by a continuous infusion with fentanyl
(20  μg/kg/h), midazolam (0.3 mg/kg/h) and pancuro-
mium bromide (0.3 mg/kg/h) to provide sedation, anal-
gesia and muscular relaxation. The right common carotid
artery was cannulated (20 G, Arrow, Erding, Germany) for
continuous blood gas and blood pressure monitoring
(Paratrend/Trendcare, Philips Medical, Böblingen, Ger-
many). A double-lumen central venous line (4.0 Fr,
Arrow) was placed in the right femoral vein for infusion
of fluids and medication. A continuous infusion of 5%
dextrose was started (100 mL/kg/d) and all animals
received one dose of cefotaxime (100 mg/kg). Body tem-
perature was measured rectally and kept between 38° and
39°C.
Lavage procedure
Respiratory failure was induced by repeated saline lavage
(50 mL/kg; 37°C) as described previously [21]. LavageBMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
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procedures were repeated at 3-min interval until partial
arterial oxygen pressure (PaO2) was below 10.7 kPa at the
following ventilator settings: PIP/PEEP 25/5 cm H2O; rate
40 breaths/min; I:E ratio 1:2 and FiO2 1.0. A mean of 7 ±
3 lavage procedures were performed per animal and a
mean recovery rate of 94% of the lavage fuid was
achieved.
Experimental protocol
Within 10 min after the final lavage, animals were ran-
domly allocated (T = 0 h) to one of the three study groups
and ventilated for a period of 5 h. FiO2 was kept at 1.0 dur-
ing the whole experimental procedure. Animals that
showed no recovery from lung lavage procedures in the
different treatment groups, indicated by a PaO2 < 60 kPa,
were excluded from further analyses.
PPVOLC group
In this group (n = 5), animals with an PaO2 below 13.3 kPa
one hour after the whole-lung lavage procedure, were
applied to pulmonary recruitment, that was attained
according to the protocol previously published by van
Kaam et al [5]. The ventilatory rate was increased to 80
breaths per minute with an I:E ratio of 1:1. These settings
remained unchanged during the experiment. PEEP was
increased up to 15 cm H2O and PIP was stepwise
increased (5 cm H2O each step) to open up the lung.
Recruitment of previously collapsed alveoli during this
procedure decreased intrapulmonary shunt and thus
increased oxygenation [4]. Optimal alveolar recruitment
was defined as PaO2 levels ≥ 60 kPa [4]. The level of PIP
needed to recruit the lung was accordingly defined the
opening pressure (PIPO).
After this recruitment procedure, PIP and PEEP were
simultaneously decreased in equal steps every 2 to 3 min
until PaO2 dropped below 60 kPa, indicating increased
intrapulmonary shunting. The level of PEEP at this stage
of alveolar collapse was called the closing pressure
(PEEPC). PEEP was then raised to a level of 2 cm H2O
above PEEPC and PIP was momentarily raised to PIPO
(about 19 s) to fully recruit the lung. Thereafter, the pres-
sure amplitude was set to keep the partial arterial carbon
dioxide pressure (PaCO2) within the target range (4–6
kPa). PEEP only was decreased if there were signs of alve-
olar overdistension such as increasing PaCO2, decreasing
PaO2 or decreasing blood pressure.
Surfactant group
In this group, animals were ventilated in the pressure-con-
trolled mode, applying a conventional ventilation strat-
egy, i.e. PIP/PEEP 25/5 cm H2O; rate 40 breaths/min; I:E
ratio 1:2 and FiO2 1.0.
Ten minutes after surfactant depletion with whole-lung
lavage animals received either natural bovine surfactant
(SF-RI1; Alveofact®; n = 5) or a modified surfactant with a
monomeric protein B (mon SP-B; n = 6) at a dosage of
100 mg/kg each. Details on surfactant preparations are
given below. Surfactant preparations were administered
as an intratracheal bolus under continuous chest move-
ments and maintenance of PEEP. Again the pressure
amplitude was set to keep the PaCO2 within the target
range (4–6 kPa) and PEEP was only decreased if there
were signs of alveolar overdistension such as increasing
PaCO2, decreasing PaO2 or decreasing blood pressure.
Mean arterial blood pressure, heart rate, ventilator set-
tings, and lung function variables were recorded at the
end of the instrumentation period, at the end of the lavage
procedure and every 30 minutes thereafter. Although
blood gas monitoring was available continuously to pro-
vide surveillance of ventilation, data were recorded at
these same time points.
Therapeutic surfactant preparations
Alveofact® (SF-RI1) is a chloroform/methanol extract of
bovine lungs containing phospholipids, neutral lipids
and the hydrophobic surfactant apoproteins SP-B and SP-
C as described previously [22]. The monomeric SP- B sur-
factant was prepared from SF-RI1 by selective reduction of
dimeric SP-B by addition of mercaptoethanol (ME; 50 mg
per 2 mL vial) at room temperature for 12 hours and sub-
sequent removement of ME by vacuum extraction. Except
for SP-B content subsequent analyses of the obtained sur-
factant preparations showed no significant differences
regarding their phospholipid and apo-protein profile.
Both surfactant preparations were provided as lyophilized
powder and resuspended in sterile saline 0.9% (Braun) to
a final concentration of 60 mg/mL.
Lung function variables
Tidal volumes, resistance and dynamic compliance were
measured by the Evita XL (Dräger, Lübeck, Germany) and
related to body weight in order to compensate for differ-
ent lung volumes. Ventilation efficiency index (VEI,
[ ]; [23]) and PIP-PEEP difference (ΔP)
were further calculated.
Bronchoalveolar lavage
At the end of the experiment (T = 5 h) piglets were sacri-
ficed by an overdose of phenobarbitone and bronchoalve-
olar lavage (BAL) was performed with physiological saline
(3 × 50 mL/kg). The percentage of lung lavage fluid recov-
ered was calculated and recovery of BAL fluid was compa-
rable in all animals studied. Samples were centrifuged for
10 min at 300 × g at 5°C to remove cells and membranous
VEI PRP a CO
= ××
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2
,
ΔBMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
Page 4 of 13
(page number not for citation purposes)
debris and the supernatant was processed for analyses of
surfactant protein and phospholipid concentrations.
Surfactant protein and phospholipid analyses
Protein analysis
Total BAL proteins were calculated using a commercial
assay (BCA assay, Pierce, Rockford, IL, USA). SP-B and SP-
C were analyzed using ELISA techniques as described pre-
viously [24,25].
Lipid analysis
Lipids were extracted from BALF with chloroform/metha-
nol [26], and the phospholipid content was determined
by spectrophotometric measurement of phosphorus
according to the method of Rouser et al. [27]. Individual
phospholipid classes were separated by high performance
thin-layer chromatography and quantified using scanning
densitometry as previously described [28]. Total fatty
acids were analyzed by gas-liquid chromatography
(Chrompack CP 9001, Varian, Darmstadt, Germany) fol-
lowing acid-catalyled transmethylation into fatty acid
methyl ester (FAME) as previously described [29]. For
characterization of relative content of large surfactant
aggregates (LSA), BALF was centrifuged at 48,000 × g (1 h,
4°C), the pellet was resuspended in 0.9% NaCl and
assessed for the PL-content. Recovery of PL in the pellet
was used to calculate relative LSA content.
Histologic processing
After the end of the experiment following the lung lavage
procedure, the right lung was perfused with 300 mL of a
formaldehyde (4.6%)-glutaraldehyde (0.5%)-solution for
approximately 10 minutes. Finally, the trachea was
clamped at a PEEP of 10 cmH2O, right lungs were
removed under maintenance of PEEP and submersed in
the above mentioned solution for histomorphologic anal-
yses. Tissue slides were obtained from dependent and
non-dependent parts of the right lung. Four tissue slides
were analysed from both the upper and lower lung lobe
and two slides from the middle lung lobe, respectively.
The slides were stained with hematoxylin-eosin (slides of
0.5  μm thickness). Lung histology was evaluated by a
pathologist (M.E.), blinded to the animal's group assign-
ment, according to a previously described histologic score
[30]. Variables scored for histologic evaluation were atel-
ectasis, alveolar and interstitial inflammation, alveolar
and interstitial hemorrhage, alveolar and interstitial
edema, necrosis and overdistension. The variables were
scored using a four-point scale with no injury correspond-
ing to 0 points and 4 points indicating maximum injury.
Measurements of interleukin and surfactant protein (SP) -
B and -C mRNA expression by realtime PCR
Messenger RNA (mRNA) expression of interleukin (IL) -
1β, IL-6, IL-8, IL-10 and SP- B and SP-C was measured in
tissue of the left lung lobe using the real-time RT-PCR
technique (TaqMan™). Samples were obtained from rep-
resentative parts of the upper and lower lung lobe.
Primers and probes were designed using Primer Express
software (Applied Biosystems, Foster City, USA) following
a fixed set of recommendations as described previously
[9]. Control PCRs showed no signal for genomic DNA,
proving mRNA-specifity. Primers were purchased from
Roth (Roth, Karlsruhe Germany), probes from Applied
Biosystems, respectively. Lung tissue homogenization was
performed in liquid nitrogen and total RNA was then
extracted using the acid guanidinium thiocyanate-phenol-
chloroform method (Roti Quick, Roth). Total RNA isola-
tion, random primed reverse transcription and real-time
PCR was performed following a standardized protocol as
described previously [9]. Primer and TaqMan probe
sequences are depicted in table 1. Relative quantification
was performed using the ΔΔCt method, which results in a
ratio of target gene expression and the expression of a
housekeeping or reference gene.
For housekeeping genes β-actin (A) and hypoxanthin-
guanine-phosphoribosyl-transferase (HPRT) were chosen
and validated by variation analyses in all samples.
As β-actin showed both no differences between different
experimental groups and the lowest variation in all sam-
ples, it was chosen as reference gene for further analysis.
Statistical analyses and data presentation
Results are given as mean and standard deviation (SD).
Results of real-time PCR analyses are given in arbitrary
units and were normalized to housekeeping gene expres-
sion. Data analysis was performed using SPSS for Win-
dows Version 6.1.3. As normal distribution has been
shown, two-way ANOVA with repeated measurements
was performed for analysis of lung function variables over
the time course. In order to compare outcome levels
between the groups differences from T = 5 - T = 0 were cal-
culated and one-way ANOVA was performed with post-
hoc Scheffé. Results of the histologic evaluation as well as
from determination of lavage specimen and real-time PCR
were analyzed using one-way ANOVA with posthoc Schef-
fé. Calculated p-values are given in the result section.
Results
All animals survived during the study period. There were
no statistical significant intergroup differences in age,
weight or number of lavages needed to induce the lung
injury. No air leaks were observed within the study period.
Blood gas values and lung function variables before and
immediately after lavage were comparable in the three
treatment groups (Table 2a). One animal of the natural
surfactant group and 2 animals of the mon SP-B surfactantBMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
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group did not recover after surfactant administration and
required intensified ventilation (OLC) in order to reach
PaO2 levels ≥ 60 kPa. As this alteration in treatment strat-
egy was not comparable with the other study groups, these
animals were therefore excluded from further analysis.
Thus, 13 animals were available for analyses.
No animal included for further analyses showed signs of
hemodynamic compromise. Data on hemodynamics
were not significantly different between the groups.
Gas exchange and lung function
After induction of lung injury, PaO2, dynamic compliance
and VEI were significantly reduced in all animals (see fig-
ure 1), whereas the resistance increased significantly.
PaCO2 remained largely unchanged.
Mean opening pressure was 35 ± 4 cm H2O, mean closing
pressure 8 ± 3 cm H2O in the PPVOLC group.
After experimental intervention (OLC, surfactant admin-
istration), PaO2, tidal volumes, difference of PIP-PEEP
(ΔP), resistance, VEI (p < 0.001 each) and dynamic com-
pliance (p = 0.01) significantly improved over the time
course in each treatment group (two-way ANOVA; Table
2a).
Regarding differences between the treatment groups, two-
way ANOVA testing revealed a significant difference with
respect to PaO2 (p < 0.001; figure 1) and PaCO2 (p < 0.05)
levels over the time course with declining effects in the nat
SF group 3 hours after intervention. Comparing the rela-
tive change of the variables over the study period (T = 5 -
T = 0), gas exchange variables showed a response to each
experimental strategy and the overall change did not differ
between the groups (Table 2b).
Comparable results were found for the development of
the dynamic compliance and the ΔP over the study period
with a significant difference between the study groups:
Dynamic compliance could be shown to increase up to
two-fold, with declining effects in the surfactant groups
after 3 hours (figure 1), whereas ΔP could be decreased in
all experimental groups during the observation period
with most pronounced effects in the PPVOLC and the mon
SP-B group (p = 0.001). Nevertheless, changes in dynamic
compliance or ΔP over the study period (T = 5 - T = 0) were
not statistically significantly different between the groups.
Mean airway pressure was found to be significantly higher
in the PPVOLC group compared to both surfactant treated
groups (p = 0.015; data not shown).
The tidal volumes achieved under different ventilation
strategies were significantly lower in the PPVOLC group
Table 1: Primer and TaqMan™ probes
Primer and Probe Description Primer sequences for PCR (forward (F) and reverse (R)) Probe sequences for 
TaqMan™ analysis
Hypoxanthin-guanine-phosphoribosyl-
transferase
F: 5'-TGGAAAGAATGTCTTGATTGTTGAAG-3'
R: 5'-ATCTTTGGATTATGCTGCTTGACC-3'
Probe: 5'(VIC)-ACACTGGCAAAAVAATGCAAACCTTGCT-(TAMRA)3'
β-Actin F: 5'-TCATCACCATCGGCAACG-3'
R: 5'-TTCCTGATGTCCACGTCGC-3'
Probe: 5'(VIC)-CCTTCCTGGGCATGGAGTCCTGC-(TAMRA)3'
Interleukin 1 beta (IL-1β) F: 5'-GGTTTCTGAAGCAGCCATGG-3'
R: 5'-GATTTGCAGCTGGATGCTCC-3'
Probe: 5'(FAM)-AAAGAGATGAAGTGCTGCACCCAAAACCTG-(TAMRA)3'
Interleukin 6 (IL-6) F: 5'-GGGTAGGGAAGGCAGTAGCC-3'
R: 5'-GAATCCCTCTCCACAAGCG-3'
Probe: 5'(FAM)-CTTCAGTGGAGTCGCCTTCTCCCTAA-(TAMRA)3'
Interleukin 8 (IL-8) F: 5'-TTCTGCAGCTCTCTGTGAGGC-3'
R: 5'-GGTGGAAAGGTGTGGAAGTC-3'
Probe: 5'(FAM)-TTCTGGCAAGAGTAAGTGCAGAACTTCGATG-(TAMRA)3'
Interleukin 10 (IL-10) F: 5'-TTGGAGCTTGCTAAAGGCACT-3'
R: 5'-CGGCGCTGTCATCAATTTCT-3'
Probe: 5'(FAM)-CACCTCCTCCACGGCCTTGCTCTT-(TAMRA)3'
Surfactant protein B (SP-B) F: 5'-TCC GCT GGT CGT TGA TCA C-3'
R: 5'-GTT TGC ACA GGC CCA AGT G-3'
Probe: 5'(FAM)-CAG AGC CAA ATG AAC CTG AAG GCC ATC-(TAMRA)3'
Surfactant protein C (SP-C) F: 5'-CAC CTT CTC CAT TGG CTC TAG TG-3'
R: 5'-ATA CTC TGC GGA GAC ATC TTC ATG-3'
Probe: 5'(FAM)-TGA CTA CCA GCG GCT CCT GAT TGC C-(TAMRA)3'BMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
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over the whole study period compared to both surfactant
groups (p = 0.002). Relative changes of tidal volumes (T =
5 - T = 0) showed a significant decline in the mon SP-B
group when compared to the nat SF group (p < 0.05 vs nat
SF).
Improved VEI were found in all treatment groups but dif-
fered in its time course between the groups (p = 0.015; fig-
ure 2). Most pronounced effects were seen in the PPVOLC
and the mon SP-B group, although effects decreased in the
mon SP-B group towards the end of the observation
period (figure 2). The relative change of the VEI over the
observation period (T = 5-T = 0) was found to be signifi-
cantly greater in the PPVOLC group compared to the mon
SP-B and nat SF treated group (p < 0.05; figure 2).
Lung histology
Lung histology was examined in tissue slices of the right
upper, middle and lower lung lobes. All study groups
revealed significantly higher histologic scores in the upper
and lower lung lobe compared to the middle lung lobe (p
< 0.05, data not given in detail). Figure 3 shows the histo-
Table 2: Gas exchange and lung function variables
a. Gas exchange and lung function variables at different time points
Pao2 PaCO2 Cdyn/kg VT/kg Res VEI ΔP
Healthy (H)
PPVOLC 74.21 ± 16.75 5.67 ± 2.05 1.94 ± 0.89 16.0 ± 4.8 37.62 ± 8.09 0.29 ± 0.17 10.20 ± 0.45
mon SP-B 64.11 ± 34.10 3.75 ± 0.75 2.56 ± 0.50 20.4 ± 2.7 40.50 ± 8.63 0.35 ± 0.08 10.00 ± 0.00
nat SF 78.44 ± 15.09 5.29 ± 1.95 2.12 ± 0.87 19.2 ± 7.0 37.88 ± 7.43 0.29 ± 0.14 10.25 ± 0.50
Lavaged (T = 0)
PPVOLC 6.70 ± 3.04 ** 6.95 ± 2.84 0.56 ± 0.23 * 11.3 ± 2.6 52.43 ± 13.53 * 0.10 ± 0.06 * 20.00 ± 0.00
mon SP-B 9.24 ± 0.79* 3.86 ± 1.64 1.21 ± 0.42 * 21.0 ± 5.0 63.28 ± 15.30 * 0.11 ± 0.02 ** 20.00 ± 0.00
nat SF 8.16 ± 1.26 ** 5.57 ± 1.35 0.88 ± 0.35 * 16.3 ± 5.4 50.25 ± 11.95 * 0.10 ± 0.04 * 20.00 ± 0.00
1 h
PPVOLC 9.68 ± 2.26 6.91 ± 2.07 0.57 ± 0.20 11.3 ± 4.5 47.50 ± 12.90 0.09 ± 0.04 20.00 ± 0.00
mon SP-B 38.60 ± 24.14 3.83 ± 2.84 1.52 ± 0.66 22.9 ± 8.4 58.55 ± 14.04 0.16 ± 0.09 19.50 ± 1.00
nat SF 56.86 ± 14.62 3.75 ± 1.13 1.50 ± 0.43 23.1 ± 6.2 53.98 ± 14.52 0.14 ± 0.05 20.00 ± 0.00
2 h
PPVOLC 71.45 ± 20.29 4.49 ± 1.97 1.03 ± 0.38 10.2 ± 2.2 34.34 ± 8.13 0.33 ± 0.20 12.60 ± 1.82
mon SP-B 64.87 ± 29.48 3.51 ± 0.91 1.53 ± 0.10 16.1 ± 7.0 47.80 ± 20.69 0.33 ± 0.27 13.75 ± 3.86
nat SF 75.18 ± 19.67 4.12 ± 0.41 1.39 ± 0.31 18.6 ± 4.0 45.20 ± 7.52 0.16 ± 0.02 17.75 ± 1.71
3 h
PPVOLC 74.08 ± 12.99 5.19 ± 2.35 1.13 ± 0.75 9.9 ± 3.0 34.76 ± 10.65 0.30 ± 0.19 12.40 ± 2.07
mon SP-B 59.05 ± 33.81 4.77 ± 1.11 1.23 ± 0.14 14.7 ± 4.1 50.63 ± 14.95 0.19 ± 0.12 14.00 ± 3.74
nat SF 72.32 ± 17.01 4.81 ± 0.55 1.15 ± 0.30 17.1 ± 5.0 43.85 ± 9.29 0.15 ± 0.04 17.00 ± 0.82
4 h
PPVOLC 70.09 ± 12.32 5.54 ± 1.67 1.11 ± 0.73 9.7 ± 2.4 35.46 ± 7.11 0.26 ± 0.15 12.60 ± 3.21
mon SP-B 60.05 ± 33.26 4.73 ± 1.28 1.21 ± 0.15 14.8 ± 3.4 53.70 ± 19.89 0.18 ± 0.11 14.50 ± 3.87
nat SF 56.53 ± 11.97 5.37 ± 0.53 1.05 ± 0.27 15.5 ± 2.8 44.18 ± 11.66 0.14 ± 0.04 16.50 ± 0.58
5 h
PPVOLC 71.61 ± 9.23 5.25 ± 1.01 0.97 ± 0.51 9.6 ± 3.2 35.78 ± 8.46 0.25 ± 0.14 12.80 ± 3.27
mon SP-B 60.38 ± 33.21 5.49 ± 1.17 1.04 ± 0.22 13.1 ± 3.7 51.93 ± 14.55 0.16 ± 0.08 14.0 ± 4.69
nat SF 48.94 ± 20.65 5.20 ± 0.52 1.01 ± 0.25 15.0 ± 2.2 50.55 ± 13.11 0.12 ± 0.04 17.00 ± 0.82
b. Overall differences in gas exchange and lung function variables (T5 - T0)
Pao2 PaCO2 Cdyn/kg VT/kg Res VEI ΔP
T5 - T0
PPVOLC 64.90 ± 9.22 -1.71 ± 2.57 0.42 ± 0.40 -2.75 ± 0.96 -17.2 ± 5.43 0.19 ± 0.078 */§ -7.2 ± 3.27
mon SP-B 51.14 ± 33.47 1.63 ± 1.27 -0.18 ± 0.42 -8.0 ± 4.24 * -11.35 ± 13.10 0.043 ± 0.07 -6.0 ± 4.69
nat SF 40.78 ± 20.49 -0.38 ± 1.71 0.13 ± 0.27 -1.25 ± 3.59 0.3 ± 5.91 0.02 ± 0.06 -3 ± 0.82
mean ± SD; open lung concept positive pressure ventilation (PPVOLC; n = 5); surfactant treatment under conventional positive pressure ventilation: 
natural bovine surfactant (Alveofact®; nat SF; n = 4), monomeric surfactant protein B based surfactant (mon SP-B; n = 4). * p < 0.05; ** p < 0.01 vs 
initial values (healthy; H). Further levels of significance (two-way ANOVA) are given in detail in the text.
* p < 0.05 vs nat SF
§ p < 0.05 vs mon SP-BBMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
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logical sum score of the different treatment groups.
Although there was a tendency towards lower sum scores
in the mon SP-B group (27 ± 20) compared to the PPVOLC
group (46 ± 17) and the nat SF group (41 ± 23) there was
no significant difference.
Surfactant protein (SP) and phospholipid analyses
Total phospholipid and total protein content, phospholi-
pid class profiles, total lipids fatty acid profiles, recovery
of large surfactant aggregates and surfactant proteins (SP)-
B and -C, were determined in cell depleted BAL specimen
Ventilation efficiency index (VEI) Figure 2
Ventilation efficiency index (VEI). Left panel. Time course of ventilation efficiency index (VEI) over the observation period. 
Induction of lung injury by repetitive lavage procedures (T = 0) is followed by open lung concept positive pressure ventilation 
(PPVOLC; n = 5) or surfactant treatment under conventional positive pressure ventilation with a natural bovine surfactant 
(Alveofact®; nat SF; n = 4) or a modified monomeric surfactant protein B surfactant (mon SP-B; n = 4). Right panel. Difference 
of VEI over the study period (T5-T0). Study groups: open lung concept positive pressure ventilation (PPVOLC; n = 5); surfactant 
treatment under conventional positive pressure ventilation with a modified monomeric surfactant protein B surfactant (mon 
SP-B; n = 4) or a natural bovine surfactant (Alveofact®; nat SF; n = 4). Results are given as mean and standard deviation. * p < 
0.05 vs PPVOLC.
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Gas exchange(PaO2) and lung function (Cdyn) Figure 1
Gas exchange(PaO2) and lung function (Cdyn). Time course of PaO2 (left panel) and dynamic compliance (Cdyn; right panel) 
over the observation period. Induction of lung injury by repetitive lavage procedures (T = 0) is followed by open lung concept 
positive pressure ventilation (PPVOLC; n = 5) or surfactant treatment under conventional positive pressure ventilation with a 
modified monomeric surfactant protein B surfactant (mon SP-B; n = 4) or a natural bovine surfactant (Alveofact®; nat SF; n = 
4). Results are given as mean and standard deviation.
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and are displayed in table 3. Total PL concentrations were
elevated up to 3-fold in both surfactant groups with signif-
icant differences between the nat SF group compared to
the PPVOLC group (p = 0.012; table 3). Total protein con-
tent was not different between the study groups, resulting
in an increase of the phospholipid-to-protein ratio ratio
in both surfactant groups compared to the PPVOLC group
(nat SF p = 0.05; mon SP-B p = 0.09). Regarding phos-
pholipid composition, the relative content of phosphati-
dylcholine and phosphatidylglycerol was found to be
significantly increased in both surfactant groups (p < 0.05
vs PPVOLC) and reached near normal levels. Accordingly,
the relative content of phosphatidylserine, phosphatidyli-
nositol, phosphatidylethanolamine and sphingomyelin
decreased in the mon SP-B and nat SF groups with signif-
icant effects for phosphatidylserine (p < 0.001 vs PPVOLC).
Analyses of the total fatty acids revealed a significantly
increased relative content of palmitic acid in both sur-
factant groups (p < 0.01 vs PPVOLC; table 3) whereas levels
of polyunsaturated fatty acids and all unsaturated fatty
acids decreased significantly (p < 0.01 vs PPVOLC). Levels
of arachidonic acid decreased in both surfactant groups
compared to the PPVOLC  group, eicospentaenoic acid
increased in the nat SF treated group (p < 0.01 vs PPVOLC).
The relative content of large surfactant aggregates was
increased in the surfactant-treated groups compared to
PPVOLC (nat SF p = 0.06; mon SP-B p = 0.048). Both, total
Histological sum scores (upper, middle and lower right lung lobe) Figure 3
Histological sum scores (upper, middle and lower right lung lobe). Histologic sum scores (atelectasis, alveolar and 
interstitial inflammation, alveolar and interstitial hemorrhage, alveolar and interstitial edema, necrosis and overdistension) of 
upper, middle and lower right lung lobe using a four-point scale with no injury corresponding to 0 points and 4 points indicating 
maximum injury (A). Comparison of the groups showed no significant differences. Hematoxylin-eosin staining of exemplary 
histologic slides showing dystelectasis and neutrophiles in nearly all alveoli in the PPVOLC group (B), regularly ventilated lung 
parenchyma in the monomeric SP-B group (C) and dystelectasis and neutrophiles in some of the alveoli in the natural SF group 
(D; hematoxylin-eosin, magnification 100×). Study groups: open lung concept positive pressure ventilation (PPVOLC; n = 5); sur-
factant treatment under conventional positive pressure ventilation with a modified monomeric surfactant protein B surfactant 
(mon SP-B; n = 4) or a natural bovine surfactant (Alveofact®; nat SF; n = 4). Results are given as mean and standard deviation.
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SP-B and SP-C concentrations were not statistically differ-
ent between the experimental groups. Nevertheless, levels
were significantly lower in the surfactant groups com-
pared to the PPVOLC group (p < 0.001) when normalized
to the total PL content of each sample.
Interleukin and surfactant protein B and C mRNA 
expression analysis
Interleukin and SF mRNA expression was determined in
the upper and lower left lung lobes. As there were no sig-
nificant differences between the results obtained from the
upper and lower left lung lobes, means were calculated
and used for further analyses. Results normalized to β-
Actin are represented in table 4. Normalization to the
housekeeping gene HPRT confirmed the results.
Analyses of the pulmonary interleukin mRNA expression
in the left lung revealed no significant differences between
the study groups. Nevertheless, there was a tendency
towards increased mRNA expression levels of the pro-
inflammatory cytokines IL-1β, IL-6 and IL-8 in the nat SF
group compared to mon SP-B and the PPVOLC group (p =
0.1; table 4). Furthermore, mRNA expression of the anti-
inflammatory cytokine IL-10 showed a tendency towards
increased levels in both surfactant groups compared to the
PPVOLC group (p = 0.1; table 4). Furthermore, SP-B and -C
mRNA expression were found to be not significantly dif-
ferent. However, SP-C mRNA expression was shown to be
tendentially increased in the mon SP-B and nat SF groups
compared to the PPVOLC group (table 4).
Discussion
Respiratory failure often accompanies critical illness and
determines morbidity in term neonates. Thus, evaluation
of therapeutic strategies in neonatal ARDS-like lung disor-
ders remains an important issue as demonstrated by a
multitude of experimental and clinical studies [19,31].
Several concepts of treatment have been established in the
last years. Under these, surfactant treatment is an estab-
lished therapeutic option, as secondary surfactant defi-
ciency may be causally related to the clinical picture and a
potential cause for the impairment in lung function. Nev-
ertheless, surfactant treatment is a very cost-intensive ther-
apy and surely has its limitations due to adverse effects or
the need for repetitive doses. Thus, conventional ventila-
tion is often used as first-line management of the disease.
If conventional ventilation strategies fail, further treat-
ment regimes are searched for in order to minimize venti-
lator-induced lung injury [32]. Thus, ventilation
following the open lung concept is often used as a rescue
therapy. Nevertheless, there is still no consensus on venti-
lation strategy in these infants in combination or without
surfactant administration until now [10]. Furthermore,
different treatment regimes as exogenous surfactant
administration under conventional ventilation or applica-
tion of open lung ventilation strategies without surfactant
Table 4: Pulmonary cytokine and surfactant protein mRNA expression (left lung lobe)
group n (piglets) IL-1β/A IL-6/A IL-8/A IL-10/A SP-B/A SP-C/A
PPVOLC 5 0.73 ± 0.51 1.27 ± 1.21 0.10 ± 1.3 0.34 ± 0.16 2.84 ± 2.17 0.82 ± 0.65
mon SP-B 4 0.35 ± 0.38 0.59 ± 0.78 0.03 ± 0.04 0.62 ± 0.32 4.05 ± 2.31 1.67 ± 0.87
nat SF 4 2.10 ± 1.77 3.96 ± 3.82 0.23 ± 0.22 0.67 ± 0.2 2.95 ± 1.27 1.09 ± 0.35
Normalization to β-Actin (A). Values are given as fold change (2-ΔΔCt). Means were calculated from values of upper and lower lung lobe.
Table 3: Phospholipid and surfactant protein analyses of lavage specimen
group n 
(piglets)
PL [μg/ml] PPQ LSA [% PL] SP-B/PL 
[% (w/w)]
SP-C/PL 
[% (w/w)]
PC [%] PG [%] PS [%] PI [%]
PPVOLC 5 48.65 ± 7.99 0.08 ± 0.01 47.7 ± 4.4 13.71 ± 3.08 3.06 ± 0.28 73.84 ± 5.57 3.59 ± 1.82 3.97 ± 2.44 6.87 ± 2.37
mon SP-B 4 131.10 ± 59.69 0.33 ± 0.16 62.7 ± 5.3 4.78 ± 2.01** 1.23 ± 0.45** 81.87 ± 1.38* 7.27 ± 2.25* 0.00 ± 0.00** 3.87 ± 1.94
nat SF 4 176.03 ± 68.91** 0.37 ± 0.21* 63.6 ± 6.2* 6.19 ± 1.73** 1.06 ± 0.62*** 81.19 ± 1.43* 8.44 ± 1.10** 0.00 ± 0.00** 3.52 ± 0.79
group n 
(piglets)
PE [%] SPH [%] PUFA [%] Usat FA [%] TL 16:0 [%] Tlfa 20:4 
(AA) [%]
Tlfa 20:5
 (EPA) [%]
PPVOLC 5 7.94 ± 3.63 3.80 ± 1.42 19.94 ± 1.39 40.34 ± 1.41 44.78 ± 1.73 5.54 ± 0.55 0.16 ± 0.03
monSP-B 4 4.99 ± 1.21 2.02 ± 0.85 12.16 ± 3.76** 33.19 ± 3.27** 52.97 ± 3.78** 3.03 ± 0.71** 0.15 ± 0.02
nat SF 4 0.47 ± 0.18 2.11 ± 0.81 11.52 ± 3.09** 35.76 ± 1.78* 50.24 ± 2.17** 2.58 ± 0.82*** 0.29 ± 0.06**
PPQ (phospholipid-to-protein ratio); Phospholipid classes are given as percent (w/w) of all phospholipids. LSA = large surfactant aggregates, given as percent (w/w) of all BALF 
phospholipids. PC (phosphatidylcholine); PG (phosphatidylglycerol); PS (phosphatidylserine); PI (phosphatidylinositol); PE (phosphatidylethanolamine); SPH (sphingomyelin); Fatty 
acids were dermined in the BAL total lipid fraction and are given as percent (w/w) of all fatty acids. PUFA (polyunsaturated fatty acids in the total lipid fraction); TL 16:0 (palmitic 
acid in the total lipid fraction). AA = Arachidonic acid, EPA = Eicospentaenoic acid
* p < 0.05 vs PPVOLC; ** p < 0.01 vs PPVOLC; ***p < 0.001 vs PPVOLC
§ p < 0.05 vs mon SP-B; §§ p < 0.01 vs mon SP-BBMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
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replacement may result in differing effects on gas
exchange, lung function, surfactant homoeostasis or pul-
monary inflammatory processes and thus short and long
term pulmonary outcome following neonatal ARDS.
In the present study, both treatment strategies investi-
gated, administration of exogenous surfactant under con-
ventional ventilation as well as application of the OLC,
were found to be efficient in improving gas exchange and
reconstituting lung function in neonatal ARDS. The effects
on lung function and gas exchange have been confirmed
for each treatment strategy in previous experimental stud-
ies [4,7,18].
To experimentally assess the effects of exogenous sur-
factant administration in neonatal ARDS compared to the
OLC, a standard treatment regime using natural bovine
surfactant has been chosen. However, surfactant prepara-
tions with varying protein and phospholipid contents
have gained increasing interest in treatment of ARDS-like
lung failure [11-13]. As native SP-B in humans is secreted
in the alveoli predominantly in its dimeric form, modifi-
cation of the dimeric structure leads to differences in the
function of SP-B and is currently under further investiga-
tion [33,34]. Recently, modification of a natural sur-
factant preparation (SF-RI1) into a monomeric SP-B
content has been demonstrated to improve biological
activity compared to standard preparations in vivo [20].
Thus, the monomeric SP-B surfactant has been chosen as
an alternative surfactant treatment in the present model.
Regarding the effects of the different treatment regimes
applied on lung function and gas exchange in detail, the
decrease of PaO2 levels in the natural surfactant group at
the end of the study period might reflect the need for
repetitive doses of surfactant to achieve sustained treat-
ment effects and may be a consequence of surfactant inac-
tivation in the alveolar compartment [35]. Furthermore,
levels of dynamic compliance did not reach initial values
during the observation period and treatment effects
declined to the end of the study period in the surfactant
treated groups. In line with our findings, van Kaam and
colleagues have shown a dose-dependency of the sur-
factant effect whereas a time-dependency with declining
effects over time could be shown in the present study [36].
Besides the the need for repetitive or increased doses of
exogenous surfactant the indicated effects may also be due
to ventilator-induced lung injury under the conventional
ventilation regime in the surfactant treated animals.
Improvement of VEI over the study period was found to
be most pronounced in the PPVOLC group, which may
reflect the potential of this ventilation strategy to more
equal recruitment of different parts of the lung. In con-
trast, surfactant is known to preferably reach lower lung
lobes and its administration therefore often leads to inho-
mogenous recruitment and holds the risk of partial over-
distension. However, ΔP values could be reduced in all
study groups possibly leading to a reduction of shear
stress and therefore traumatic lesions in the lung in the
experimental ventilatory setting.
In order to define the impact of the treatment strategies
applied on lavage-induced lung injury, surfactant homoe-
ostasis and inflammatory processes, histologic patterns,
cytokine and surfactant mRNA expression as well as
phosholipid profiles of BALF were investigated.
Regarding histologic patterns, the evaluated score com-
prising different variables indicating the degree of lung
injury showed no significant differences between the
groups. Nevertheless, analyses showed alterations to pul-
monary tissue, reflecting the delay of structural recovery
compared to reconstitution of lung function and gas
exchange after indcution of neontatal ARDS-like lung
injury. The monomeric SP-B preparation revealed a ten-
dency to improvement in lung structure, which may sug-
gest the altered surfactant preparation to be effective in
influencing surfactant homeostasis and thus the recovery
in physiologic lung function.
Alterations to the surfactant system have been shown to
closely reflect lung injury processes, especially alveolar
type-II cell integrity and metabolism [25,28,37]. Further-
more, reconstitution of the surfactant system has been dis-
cussed as an important measure assessing different
treatment regimes in ARDS-like lung disorders in children
and infants. As expected, the phospholipid profile in BAL
specimen showed a normalization of the phospholipid
and fatty acid profile in both surfactant groups with an
increase in concentrations of phosphatidylcholine and
phosphatidylglycerol as well as the palmitic acid concen-
tration in the total lipid fraction. In contrast, the phos-
pholipid analyses of the PPVOLC group showed the typical
profile for ARDS-like lung failure with a reduced recovery
of phosphatidylcholine and phosphatidylglycerol, an
increased relative content of polyunsaturated fatty acids,
i.e. arachidonic acid and a decreased relative content of
palmitic acid [28,37]. Furthermore, the relative content of
large surfactant aggregates and the phospholipid-to-pro-
tein ratio in the BALF were significantly reduced in the
PPVOLC  group. These findings reflect a significantly
reduced recovery of the surfactant system in the PPVOLC
ventilated animals compared to the surfactant treated
groups, potentially leading to short and long term conse-
quences regarding lung injury processes and pulmonary
function. Regarding the surfactant protein concentrations
in the BALF, levels were comparabel in all study groups. In
the case of SP-C, this may suggest a stabilization of type-II
cell integrity and surfactant homeostasis under the indi-
cated treatment regimes as previous studies showed signif-BMC Pulmonary Medicine 2008, 8:10 http://www.biomedcentral.com/1471-2466/8/10
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icantly reduced SP-C levels in BAL specimen from
conventionally ventilated ARDS patients [25]. An early
recovery of alveolar type-II cell integrity and metabolism
after lavage-induced lung injury may be further indicated
by tendentially increased SPC mRNA expression in the in
the surfactant treated groups.
Nevertheless, the combination of both treatment strate-
gies will gain increasing interest as shown by latest studies
[2,38]. Here, open lung ventilations strategies after exoge-
nous surfactant administrations allowed reduction of
both the opening and the closing pressures after some
hours, which may be explained by a higher alveolar stabi-
lization after recruitment maneuvers in combination with
the effect of surfactant administration. Futhermore, the
present study showed the relative SP-B and SP-C concen-
tration after normalization to the total PL content of each
sample, to be lower in the surfactant-treated groups. This
may be assigned to a higher rate of ventilator-induced
lung injury in the conventionally ventilated, surfactant
treated animals, where higher ΔP values and tidal volumes
compared to the PPVOLC group may led to an increased
rate of shear stress to the lung. On the other hand, a shift
in the phospholipid-to-protein ratio ratio may result from
surfactant administration, as the indicated preparations
contain relevant amounts of phopsholipids. Furthermore,
limits of surfactant treatment in combination with a con-
ventional ventilation strategy are demonstrated by cases
with an absent response to exogenous surfactant adminis-
tration as one animal in the natural surfactant and two
animals in the monomeric SP-B group did not recover
from lung failure and required an intensified ventilation
regime.
In terms of pulmonary inflammatory processes, previous
studies have been shown for the OLC ventilation to
reduce signs of inflammation in BALF when compared to
conventional ventilation strategies [4]. In the present
study analyses of pulmonary pro-inflammatory cytokine
mRNA expression showed no significant differences
between the OLC and the surfactant treated groups. How-
ever, mRNA expression of the anti-inflammatory cytokine
IL-10 showed a tendency towards increased levels in the
surfactant groups compared to the PPVOLC group, possibly
indicating anti-inflammatory or lung protective effects of
exogenous surfactant. The tendency towards increased IL-
1β, IL-6 and IL-8 mRNA expression in the natural sur-
factant group has also previously been shown in vivo for
natural surfactant treated animals in a model of experi-
mental meconium aspiration syndrome [9] and for
endothelial cell activation in vitro [39] and may be
explained by a higher concentration of arachidonic acid in
the natural surfactant preparation.
In conclusion, we could show in a descriptive manner
both treatment strategies, the administration of exoge-
nous surfactant under conventional ventilation as well as
the application of an intensified mechanical ventilation
concept following the OLC to be efficient in improving
lung function and gas exchange in neonatal ARDS. Never-
theless, administration of surfactant led to a more pro-
nounced effect on gas exchange and compliance in the
first hours, although improvement in oxygenation
declined after 3 hours in the natural surfactant group. In
contrast, improvement in VEI was found to be more evi-
dent in the PPVOLC group. Thus, differences between the
surfactant and the PPVOLC groups regarding maintenance
of the effects on lung function as well as surfactant
homoeostasis and the pulmonary inflammatory balance
may lead to pulmonary long-term consequences which
should be addressed in further studies. Limitations of the
study, that need to be addressed are the potential induc-
tion of lung injury processes by the initial phase of con-
ventional ventilation, the induction of lung injury using
repeated lavage procedures with each lavage volume
potentially beyond total lung capacity leading to non-
physiologic stretch as well as the application of relatively
high tidal volumes in the PPVOLC group compared to
previously published study settings applying OLC ventila-
tion regimes. Changing ventilation strategies and modify-
ing existing concepts reflect everyday clinical practice, but
further studies are needed to address the impact of these
variables on pulmonary outcome. As well clinical studies
are needed in order to verify findings from animal studies.
As the results indicate differing surfactant preparations to
reveal distinct effects on lung function variables, further
studies are needed to define an optimized surfactant com-
position.
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